<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1416">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142722</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-302</org_study_id>
    <nct_id>NCT05142722</nct_id>
  </id_info>
  <brief_title>Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies</brief_title>
  <acronym>BROADWAY</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD and LDL-C ≥70 and &lt;100 mg/dL Who Are Not Adequately Controlled by Their Lipid Modifying Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewAmsterdam Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewAmsterdam Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 3 study in&#xD;
      participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD&#xD;
      to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and&#xD;
      maximally tolerated lipid-lowering therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 3 study in&#xD;
      participants with underlying HeFH and/or ASCVD to evaluate the efficacy, safety, and&#xD;
      tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering&#xD;
      therapy. The screening period for this study will take up to 28 days. Afterwards patients&#xD;
      will be randomized to placebo or 10 mg obicetrapib for an 365 day treatment period. After the&#xD;
      treatment period, patients will have an end of study follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled, double-blind, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo tablet made to resemble active</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Percent change from baseline to Day 84 in LDL-C</time_frame>
    <description>obicetrapib compared to placebo on LDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein B (ApoB)</measure>
    <time_frame>Percent change from baseline to Day 84 in ApoB</time_frame>
    <description>obicetrapib compared to placebo on ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-HDL-C</measure>
    <time_frame>Percent change from baseline to Day 84 in non-HDL-C</time_frame>
    <description>obicetrapib compared to placebo on non-HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>Percent change from baseline to Day 84 in HDL-C</time_frame>
    <description>obicetrapib compared to placebo on HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Percent change from baseline to Day 180 in LDL-C</time_frame>
    <description>obicetrapib compared to placebo on LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Percent change from baseline to Day 365 in LDL-C</time_frame>
    <description>obicetrapib compared to placebo on LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac event (MACE)</measure>
    <time_frame>Baseline to end of study (30 days post last dose; approximately Day 395)</time_frame>
    <description>evaluate the effect of obicetrapib on the risk of MACE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>High Cholesterol</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obicetrapib 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 10mg obicetrapib tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet made to resemble active</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obicetrapib</intervention_name>
    <description>10mg obicetrapib tablet</description>
    <arm_group_label>obicetrapib 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females may be enrolled if all 3 of the following criteria are met:&#xD;
&#xD;
          -  They are not pregnant;&#xD;
&#xD;
          -  They are not breastfeeding; and&#xD;
&#xD;
          -  They do not plan on becoming pregnant during the study;&#xD;
&#xD;
          -  Have underlying heterozygous familial hypercholesterolemia (HeFH) and/or a history of&#xD;
             established ASCVD with additional risk factors&#xD;
&#xD;
          -  Are on maximally tolerated lipid-modifying therapy, including a maximally tolerated&#xD;
             statin, at a stable dose for at least 4 weeks prior to Screening&#xD;
&#xD;
          -  Atorvastatin 40 or 80 mg; or&#xD;
&#xD;
          -  Rosuvastatin 20 or 40 mg;&#xD;
&#xD;
          -  Fasting serum LDL-C ≥70 and &lt; 100 mg/dL (≥1.8 and &lt;2.6 mmol/L) at Screening;&#xD;
&#xD;
          -  Fasting triglyceride (TG) &lt; 400 mg/dL (&lt;4.52 mmol/L) at Screening; and&#xD;
&#xD;
          -  Have an estimated glomerular filtration rate (eGFR) ≥30 mL/min at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association class IV heart failure or last known left ventricular&#xD;
             ejection fraction &lt; 25%;&#xD;
&#xD;
          -  Major adverse cardiac event (MACE) within 3 months prior to Randomization;&#xD;
&#xD;
          -  Uncontrolled severe hypertension, defined as either systolic blood pressure ≥ 160 mmHg&#xD;
             or diastolic blood pressure ≥100 mmHg prior to Randomization;&#xD;
&#xD;
          -  Formal diagnosis of homozygous familial hypercholesterolemia (HoFH);&#xD;
&#xD;
          -  Active liver disease;&#xD;
&#xD;
          -  HbA1c ≥10% at Screening;&#xD;
&#xD;
          -  Thyroid-stimulating hormone &gt;1.5 X upper limit of normal (ULN) at Screening;&#xD;
&#xD;
          -  Creatine kinase 3 X upper limit of normal (ULN) at Screening;&#xD;
&#xD;
          -  History of malignancy that required surgery (excluding local and wide local excision),&#xD;
             radiation therapy, and/or systemic therapy during the 3 years prior to Randomization;&#xD;
&#xD;
          -  Known history of alcohol and/or drug abuse within 5 years prior to Screening;&#xD;
&#xD;
          -  Received treatment with other investigational products or devices within 30 days of&#xD;
             Screening or 5 half-lives of the previous investigational product, whichever is&#xD;
             longer;&#xD;
&#xD;
          -  Planned use of other investigational products or devices during the course of the&#xD;
             study;&#xD;
&#xD;
          -  Participated in any clinical trial evaluating obicetrapib; or&#xD;
&#xD;
          -  Known allergy or hypersensitivity to obicetrapib, placebo, or any of the excipients in&#xD;
             obicetrapib or placebo&#xD;
&#xD;
          -  Any condition that, according to the Investigator, could interfere with the conduct of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ditmarsch</last_name>
    <role>Study Director</role>
    <affiliation>NewAmsterdam Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Brown</last_name>
    <phone>513-579-9911</phone>
    <phone_ext>12803</phone_ext>
    <email>j.brown3@medpace.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Creager</last_name>
    <phone>513-579-9911</phone>
    <phone_ext>11256</phone_ext>
    <email>J.Creager@Medpace.com</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obicetrapib</keyword>
  <keyword>BROADWAY</keyword>
  <keyword>Cholesteryl ester transfer protein (CETP) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

